Elucid vs Hyperfine Swoop

Elucid's PlaqueIQ analyses coronary CT angiograms that a physician sends in, and a cardiology group with CCTA volume is its buyer. Hyperfine's Swoop is a 0.064T brain MRI that goes to the bedside without a shielded room, and an ICU where conventional MRI is undesirable or impossible is its buyer. Hyperfine publishes no Swoop dollar price. Its FY2025 10-K describes ownership plus an annual software and service agreement after a one-year warranty, on 36 or 60 month terms, and puts conventional MRI at about $1.2 million, while an older research paper estimated about $50,000 per system. Hyperfine reported preliminary Q3 2026 revenue of about $6.0 million and cash near $37.9 million. Swoop images T1, T2, T2-FLAIR and DWI with no contrast-enhanced T1, the limit an ICU buyer accepts in exchange for imaging at the bedside.